Basic Information
| LncRNA/CircRNA Name | SERTAD2-3 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | OS tissues,cell lines (MG-63, U2OS, and Saos-2) |
| Expression Pattern | down-regulated |
| Function Description | lnc-SERTAD2-3, an OS suppressor, is involved in the inhibition of OS proliferation and migration by targeting miR-29c. |
| Pubmed ID | 31999493 |
| Year | 2020 |
| Title | Long Noncoding RNA SERTAD2-3 Inhibits Osteosarcoma Proliferation and Migration by Competitively Binding miR-29c |
External Links
| Links for SERTAD2-3 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |